×
| Stock | Total Income | Net Profit | Net Sales | EPS | Market Cap (in Cr) | P/E |
|---|---|---|---|---|---|---|
| FABINO ENTERPRISES LIMITED | NA | NA | NA | NA | 5.46 | 91.0 |
| Triochem Products Ltd., | NA | NA | NA | NA | 0 | |
| PANACEA BIOTEC LTD. | 1172.0 | -67.0 | 1122.5 | -1.09 | 2,762 | |
| MOREPEN LABORATORIES LTD. | 3953.77 | 80.61 | 3912.84 | 0.15 | 2705 | 29.2 |
| Krsnaa Diagnostics Limited | 1796.13 | 195.62 | 1756.15 | 6 | 2688 | 33.5 |
Panacea Biotec Ltd., with Security Code 531349, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.
| Metrics | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 75.0 | 89.4 | 94.6 | 95.2 | 80.4 | 56.9 | 76.6 | 108.4 | 67.9 | 112.3 |
| Expenses | 71.6 | 82.6 | 84.6 | 88.6 | 89.6 | 67.4 | 69.9 | 93.0 | 86.5 | 115.3 |
| Operating Profit | 3.4 | 6.8 | 10.0 | 6.6 | -9.2 | -10.5 | 6.7 | 15.4 | -18.6 | -3.0 |
| OPM % | 4.57% | 7.62% | 10.53% | 6.97% | -11.5% | -18.44% | 8.79% | 14.19% | -27.32% | -2.69% |
| Other Income | 10.3 | 3.3 | 2.1 | 3.1 | 16.4 | 3.8 | 3.4 | 3.3 | 6.1 | 5.0 |
| Interest | 2.7 | 3.5 | 3.6 | 3.4 | 3.4 | 3.2 | 3.8 | 3.9 | 4.6 | 6.0 |
| Depreciation | 5.9 | 5.4 | 5.3 | 5.2 | 5.1 | 5.1 | 5.1 | 5.2 | 4.9 | 4.8 |
| Profit before tax | 5.1 | 1.3 | 3.2 | 1.1 | -1.4 | -15.0 | 1.3 | 9.7 | -22.0 | -8.8 |
| Tax % | -486.1% | 0% | 0% | -59.8% | 1.5% | -8% | -0.8% | 0% | 0% | 24.2% |
| Net Profit | -19.7 | 1.3 | 3.2 | 0.4 | -1.4 | -13.8 | 1.3 | 9.7 | -12.4 | -6.7 |
| EPS in Rs | -3.21 | 0.21 | 0.52 | 0.07 | -0.22 | -2.25 | 0.21 | 1.58 | 0 | -1.09 |
| Metrics | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 115.2 | 128.9 | 129.2 | 143.0 | 150.5 | 136.5 | 115.7 | 147.4 | 163.5 | 132.5 |
| Expenses | 123.8 | 134.6 | 139.5 | 146.6 | 150.7 | 142.5 | 129.7 | 140.4 | 155.5 | 159.3 |
| Operating Profit | -8.6 | -5.7 | -10.3 | -3.6 | -0.2 | -6.0 | -14.0 | 7.0 | 8.0 | -26.8 |
| OPM % | -7.5% | -4.4% | -7.98% | -2.49% | -0.1% | -4.43% | -12.09% | 4.75% | 4.87% | -20.23% |
| Other Income | 41.7 | 34.4 | 33.8 | 6.0 | 8.5 | 13.6 | 6.5 | 7.4 | 6.4 | 36.3 |
| Interest | 1.0 | 1.1 | 1.0 | 0.9 | 0.9 | 0.8 | 0.9 | 1.0 | 1.0 | 1.0 |
| Depreciation | 9.7 | 9.5 | 9.5 | 9.3 | 9.1 | 8.8 | 8.7 | 8.7 | 9.0 | 8.4 |
| Profit before tax | -5.3 | -1.2 | -14.7 | -10.6 | -4.4 | -4.9 | -19.8 | 2.0 | 1.6 | -27.7 |
| Tax % | -13.7% | -169.6% | -15.7% | 6.6% | 33.3% | -6.1% | 6.9% | -1.1% | 1.4% | 0% |
| Net Profit | 19.4 | -12.7 | 11.0 | -8.3 | -2.2 | -2.0 | -15.9 | 4.7 | 4.4 | -2.0 |
| EPS in Rs | 3.16 | -2.07 | 1.79 | -1.35 | -0.37 | -0.23 | -2.59 | 0.77 | 0.74 | 0 |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -3% |
| 5 Years: | 30% |
| 3 Years: | 2% |
| TTM: | -9% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 15% |
| 3 Years: | 30% |
| TTM: | 72% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 30% |
| 3 Years: | 51% |
| 1 Year: | 270% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 1% |
| 5 Years: | 4% |
| 3 Years: | -4% |
| TTM: | 2% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 14% |
| 3 Years: | 22% |
| TTM: | 37% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 30% |
| 3 Years: | 51% |
| 1 Year: | 270% |
Recent Bets
|
Date
|
Stock
|
Party
|
Deal
|
Acq. Mode
|
Trans.
|
Quan.
|
Price
|
Value
|
|---|
| Period | SMA Value | Status |
|---|
| Period | EMA Value | Status |
|---|
| Indicator | Value |
|---|